483 Tianjin Weijie Pharmaceutical Jan 2018

483 Tianjin Weijie Pharmaceutical Jan 2018

Christopher Middendorf FDA$119.00 - Available Now

FDA investigators audited the Tianjin Weijie Pharmaceutical - Tianjin, China facility and issued inspectional observations (via FDA 483) on 11 Jan 2018.

Product details

  • Category: Human Drugs
  • Inspection end: 11 Jan 2018
  • Location: Tianjin, China
  • FEI: 3005526021
Add To Cart